Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sigma Healthcare Ltd (ASX: SIG) shares surged 9% on Thursday and are the most actively traded stock on their first day of trading post-merger with Chemist Warehouse.

The Sigma share price rose by 9.4% to an intraday high of $3.02 per share today.

The stock has since retraced a little to be trading at $2.94, up 6.52%.

The scheme of arrangement between the two companies was officially implemented yesterday, and about 4.3 billion unescrowed new Sigma shares began trading today.

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

First day of trading for repackaged Sigma Healthcare shares

At the time of writing, almost 128.5 million Sigma shares have been traded on Thursday, making it the most traded stock of the day, according to CommSec data.

Some of this trading is likely Chemist Warehouse franchisees offloading their holdings.

This blockbuster merger sure has excited the market, and today's share price leap indicates continued optimism for the future.

The Sigma share price has soared since the proposal was announced on 11 December 2023.

The excitement surrounding the deal prompted many investors to buy Sigma shares.

The new demand resulted in Sigma becoming the No. 1 ASX 200 healthcare share for price growth last year.

Sigma shareholders were thrilled with the proposed deal and voted overwhelmingly in favour of it last month.

Today, Sigma is the ASX 200's second-largest healthcare stock with a market capitalisation of $31.84 billion.

Shares held under escrow

Sigma now officially holds all of the ordinary shares in CW Group Holdings Limited, and Chemist Warehouse is now a wholly owned subsidiary of Sigma Healthcare.

A total of 9.9 billion shares were issued as part of the consideration for Sigma's purchase.

However, approximately 5.6 billion remain under escrow.

Chemist Warehouse shareholders who were entitled to receive consideration got just under 45 cents in cash and just over 6.3 new Sigma shares for each Chemist Warehouse share held.

Sigma estimated the market value of those new shares at $2.83 per share.

The 5.6 billion new Sigma shares under escrow were issued in three separate parcels to Chemist Warehouse co-founders Jack Gance and Sam Gance, and CEO Mario Verrocchi.

Sigma said the trio was "committed to the long-term value creation opportunities available to Sigma" post-merger and had therefore agreed to voluntary escrow arrangements.

Subject to certain exceptions, they cannot sell any of their escrowed shares during the First Escrow Period, defined as between now and the earlier of 31 August or the close of trading on the day that Sigma releases its financial results for the period ending 30 June this year.

They cannot sell 90% of their escrowed shares between the end of the First Escrow Period and the earlier of either 31 August 2026 or the close of trading on the day that Sigma releases its financial results for the period ending 30 June 2026.

Jack Gance and Mario Verrocchi, along with Chemist Warehouse's chief property officer Damien Gance, and chief people officer Danielle Di Pilla, have been appointed to the Sigma board.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »